Advertisement

Topics

Novartis targets specific patient population with strong Ilaris Phase 3 data

06:25 EST 14 Nov 2017 | Pharmafile

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the drug.

read more

Original Article: Novartis targets specific patient population with strong Ilaris Phase 3 data

NEXT ARTICLE

More From BioPortfolio on "Novartis targets specific patient population with strong Ilaris Phase 3 data"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...